Navigation Links
Dr. Magnus Persson Joins Cerecor's Board of Directors
Date:8/28/2012

BALTIMORE, Aug. 28, 2012 /PRNewswire/ -- Cerecor Inc. announced today that Magnus Persson, MD Ph.D. has joined the company's Board of Directors. Dr. Persson was one of the original team members at Healthcap, one of the largest biotechnology venture capital firms in Europe.  He became Partner before the first fund was raised in 1996, participated in raising in excess of US$ 1B in international institutional investments and was responsible for deal sourcing, screening and the monitoring of investments as Board representative. He invested in 85 Companies of which 24 have made successful IPO's in various European exchanges and on NASDAQ. Dr. Persson trained at the Karolinska Institute in Stockholm and prior to Healthcap led Phase II and III clinical programs in the Pharmaceutical Industry.

(Logo:  http://photos.prnewswire.com/prnh/20120411/PH85852LOGO )

Magnus currently serves on the Board of Directors of AscendxSpine (private), ConcitPharma (private), Sjalbadan (private) and the Swedish Center for Medical Nanotechnology at Karolinska Institute.  He has previously served on the Boards of Chemocentryx (public), Arpida (public), Tripep (public), PTC Therapeutics (private), Alba Therapeutics (private), Trigen (private), Apoxis (private), SpineVision (private), Carmot Therapeutics (private), MIPS Technology (private), LICA Pharmaceuticals (private), IDEA (private), Neoventa (private) and Prolifix (public).

"Magnus has a vast network within international biopharmaceutical financing communities and has a track record of delivering value for shareholders and stakeholders while expanding the potential of those people who report to him," said Blake Paterson, M.D., the CEO of Cerecor.   Dr. Persson added, "I am delighted to join the Board of Directors of Cerecor and to assist its outstanding management in building a novel and truly differentiated neuroscience Company."

In addition to Drs. Persson and Paterson, Cerecor's Board is Chaired by Dr. Sol Barer and further comprised of members Dr. Gene Bauer and Mssrs. Isaac Blech, John Catsimatidis, and Cary Sucoff.

About Cerecor:  Cerecor Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. We are a Delaware corporation, based in Baltimore and organized in April 2011 in partnership with various laboratories at Johns Hopkins Medical Institute. Cerecor is focused on translational medicine – the accelerated transfer of technology from the academic laboratory to early human trials, with the mission of commercializing therapeutics that make a difference.

Contact:  John Dierkes, Kennedy Advisors, +1-410-522-8707


'/>"/>
SOURCE Cerecor Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Joseph Rogers Joins SRI International as Executive Director of New Health Sciences Section in Biosciences Division
2. Pharmacy Industry Veteran Joins Millennium Pharmacy Systems as SVP Operations
3. Biotechnology Thought Leader, Dr. Abbie Celniker, Joins ImaginAb Board of Directors as Chairman
4. Dr. Gerald Yakatan Joins Imprimis Pharmaceuticals Science and Regulatory Advisory Board
5. MinuteClinic Joins with American Heart Association to Help Americans Reduce High Blood Pressure
6. Stephen G. Austin, CPA Joins Imprimis Pharmaceuticals Board Of Directors
7. Remedy Informatics Joins LongView International Technology Solutions Team to Win CIO-SP3 Contract Award
8. Tara Dall, MD Joins Health Diagnostic Laboratory (HDL, Inc.) as Chief Medical Officer
9. Double Helix Joins McCann Health
10. Prairie Education & Research Cooperative Joins MedNet Solutions iMedNet CRO Partner Program
11. Don Hubbard Joins Checkpoint Surgical As VP Of Sales And Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... CARLSBAD, Calif. , Feb. 8, 2016  HemaFlo Therapeutics, ... Office (USPTO) has issued US Patent Number 9,119,880 covering the ... Dale Peterson , PhD, HemaFlo,s founder, said, "We ... technology." --> Dale Peterson , PhD, HemaFlo,s ... such a powerful technology." --> Dale ...
(Date:2/8/2016)... 8, 2016  Dynatronics Corporation (NASDAQ: DYNT ... devices and rehabilitation equipment for the physical therapy, ... Broncos, football team for winning the 2016 World ... Chairman and Chief Executive Officer.  "The Broncos have ... forward to enhancing their athletic achievements with our ...
(Date:2/8/2016)... RICHMOND, Calif. , Feb. 8, 2016 /PRNewswire/ ... leader in therapeutic genome editing, announced that the ... the Company,s Investigational New Drug (IND) application for ... a life-long therapy for Mucopolysaccharidosis Type I (MPS ... and enables Sangamo to initiate a Phase 1/2 ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Brenntag Specialties, Inc.(BSI) ... Food & Beverage and Dietary Supplement market segments across ... and USA geographies east of the Rocky Mountains since 2012. Consistent performance ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... BantamPro L top-load case packer for pouches, bags, and flow wrapped products at ... help co-packers and specialty product manufacturers step up to semi-automatic or fully-automatic case ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... community enrichment program serving the greater Venice, FL area, has initiated a fundraiser ... in a car accident just four days after Christmas. To support this beautiful ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... of organizations. DocuSyst provides a cloud hosted environment for FileHold software that ... integration with various 3rd party applications using the FileHold web services API. DocuSyst ...
(Date:2/8/2016)... ... 08, 2016 , ... Joshua Rosenthal, PhD, Chief Scientific Officer ... use newly released government data on populations and physicians to better calculate risk ... the value they create to succeed in new economic models for value based ...
Breaking Medicine News(10 mins):